Stryker Corporation has experienced a notable retracement in today’s session as investors react to a confluence of fundamental concerns regarding the medical technology giant’s growth trajectory for the remainder of the year. The primary driver appears to be a cautious update regarding organic sales growth within the company’s core MedSurg and Neurotechnology segments. Market participants are increasingly concerned that the pace of hospital capital equipment spending is decelerating due to tighter credit conditions and budgetary constraints within major healthcare systems. This shift in the spending environment directly impacts Stryker’s high-value robotic surgery systems and imaging equipment, which are critical components of…